par Hepatitis C- working group for COHERE in Eurocoord, Colette;Smit, Joop;Arends, Lars;Peters, Antonella;d'Arminio Monforte, François;Dabis, Robert;Zangerle, George;Daikos, Christina;Mussini, Josep;Mallolas, Stéphane;De Wit, Annelies ;Zinkernagel, Jaime;Cosin, Geneviève;Chêne, Dorthe;Raben, Jürgen;Rockstroh,
Référence BMC infectious diseases, 15, page (498)
Publication Publié, 2015
Référence BMC infectious diseases, 15, page (498)
Publication Publié, 2015
Article révisé par les pairs
Résumé : | Contradicting results on the effect of abacavir (ABC) on hepatitis C virus (HCV) treatment responses in HIV/HCV co-infected patients have been reported. We evaluated the influence of ABC on the response to pegylated interferon (pegIFN) and ribavirin (RBV)-containing HCV treatment in HIV/HCV co-infected patients in a large European cohort collaboration, including data from different European countries. |